Effects of Antipsychotics on Bone Mineral Density in Schizophrenia

1 Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, et al. Clinician’s Guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10): 2359-81. Search in Google Scholar

2 Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115-37. Search in Google Scholar

3 World Helth Organization. Prevention and management of osteoporosis: report of a WHO scientific group. 2003;7-31. Search in Google Scholar

4 Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23-57. Search in Google Scholar

5 Crockford D, Addington D. Canadian Schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatry. 2017;62(9):624-34. Search in Google Scholar

6 National Institute for Health and Clinical Excellence (NICE). Psychosis and Schizophrenia in Adults. Treatment and Management. NICE Clinical Guideline No.178. National Collaborating Centre for Mental Health (UK). London: National Institute for Health and Clinical Excellence; 2014. Search in Google Scholar

7 Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163–91. Search in Google Scholar

8 Dar HY, Azam Z, Anupam R, Mondal RK, Srivastava RK. Osteoimmunology: The Nexus between bone and immune system. Front Biosci, Landmark. 2018;23(3):464-92. Search in Google Scholar

9 Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol. 2007;143(1):31-48. Search in Google Scholar

10 Reul, JM. Making memories of stressful events: a journey along epigenetic, gene transcription, and signaling pathways. Front Psychiatry. 2014;5,5. Search in Google Scholar

11 Gilad VH, Rabey JM, Eliyayev Y, Gilad GM. Different effects of acute neonatal stressors and long-term postnatal handling on stress-induced changes in behavior and in ornithine decarboxylase activity of adult rats. Brain Res Dev Brain Res. 2000;120(2):255-9. Search in Google Scholar

12 Ray A, Gulati K, Rai N. Stress, anxiety, and immunomodulation: a pharmacological analysis. Vitam Horm. 2017;103:1-25. Search in Google Scholar

13 Balõtšev R, Haring L, Koido K, Leping V, Kriisa K, Zilmer M, et al. Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study. Early Interv Psychiatry. 2019; 13(1):101-9. Search in Google Scholar

14 Vancampfort D, Wampers M, Mitchell AJ, Correll CU, De Herdt A, et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013;12(3):240-50. Search in Google Scholar

15 Hussain T, Margoob MA, Shoib S, Shafat M, Chandel RK. Prevalence of Metabolic Syndrome among Psychiatric Inpatients: A Hospital Based Study from Kashmir. J Clin Diagn Res. 2017;11(6):VC05-VC08. Search in Google Scholar

16 Sjo CP, Stenstrøm AD, Bojesen AB, Frølich JS, Bilenberg N. Development of metabolic syndrome in drug-naive adolescents after 12 months of second-generation antipsychotic treatment. J Child Adolesc Psychopharmacol. 2017;27(10):884-91. Search in Google Scholar

17 Popović I, Ravanić D, Janković S, Milovanović D, Folić M, Stanojević A, et al. Long-term treatment with olanzapine in hospital conditions: prevalence and predictors of the metabolic syndrome. Srp Arh Celok Lek. 2015;143(11-12):712-8. Search in Google Scholar

18 Gomez L, Stubbs B, Shirazi A, Vancampfort D, Gaughran F, Lally J. Lower bone mineral density at the hip and lumbar spine in people with psychosis versus controls: a comprehensive review and skeletal site-specific meta-analysis. Curr Osteoporos Rep. 2016;14(6):249-59. Search in Google Scholar

19 Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79-104. Search in Google Scholar

20 Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. Search in Google Scholar

21 Chen CY, Lane HY, Lin CH. Effects of antipsychotics on bone mineral density in patients with schizophrenia: gender differences. Clin Psychopharmacol Neurosci. 2016;14(3):238-49. Search in Google Scholar

22 Haddad PM, Wieck A. antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-314. Search in Google Scholar

23 Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008;18(2):S108-S114. Search in Google Scholar

24 Bulut SD, Bulut S, Tüzer V, Mehmet AK, Emine AK, Cebrail KISA, et al. The effects of prolactin-raising and prolactin-sparing antipsychotics on prolactin levels and bone mineral density in schizophrenic patients. Noro Psikiyatr Ars. 2014;51(3):205-10. Search in Google Scholar

25 Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010;12(3):345–57. Search in Google Scholar

26 Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs. 2013;27(4):249-57. Search in Google Scholar

27 Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231-41. Search in Google Scholar

28 Vieweg V, Hasnain M. Schizophrenia, antipsychotic drugs, and drug induced weight gain and obesity. Expert Rev Neurother. 2012;26(1):19-22. Search in Google Scholar

29 Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69(3):385-91. Search in Google Scholar

30 Golob AL, Laya MB. Osteoporosis: screening, prevention, and management. Med Clin North Am. 2015;99(3):587-606. Search in Google Scholar

31 Cilotti A, Falchetti A. Male osteoporosis and androgenic therapy: from testosterone to SARMs. Clin Cases Miner Bone Metab. 2009;6(3):229–33. Search in Google Scholar

32 Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23(11):576-81. Search in Google Scholar

33 Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance. L'encephale. 2014;40(1):86-94. Search in Google Scholar

34 Milano W, D’Acunto CW, De Rosa M, Festa M, Milano L, et al. A. Recent clinical aspects of hyperprolactinemia induced by antipsychotics. Rev Recent Clin Trials. 2011;6(1):52-63. Search in Google Scholar

35 Wang M, Hou R, Jian J, Mi G, Qiu H, et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol. 2014;29(2):183-9. Search in Google Scholar

36 Okita K, Kanahara N, Nishimura M, Yoshida T, Yasui-Furukori N, Niitsu T, et al. Second-generation antipsychotics and bone turnover in shizophrenia. Schizophr Res. 2014;157(1-3):137-41. Search in Google Scholar

37 Lodhi RJ, Masand S, Malik A, Shivakumar K, McAllister VD, O’Keane V, et al. Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study. Schizophr Res. 2016;170(2-3):245-51. Search in Google Scholar

38 De Hert M, Detraux J, Stubbs B. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review. Expert Opin Drug Saf. 2016;15(6):809-23. Search in Google Scholar

39 Wu H, Deng L, Zhao L, Zhao J, Li L, Chen J. Osteoporosis associated with antipsychotic treatment in schizophrenia. Int J Endocrinol. 2013;1-7. Search in Google Scholar

40 Tseng PT, Chen YW, Yeh PY, Tu KY, Cheng YS, Wu CK. Bone mineral density in schizophrenia: An up-date of current meta-analysis and literature review under guideline of PRISMA. Medicine. 2015;94(47):e1967. Search in Google Scholar

41 González-Blanco L, Greenhalgh AMD, Garcia-Rizo C, Fernandez-Egea E, Miller BJ, Kirkpatrick B. Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: a meta-analysis. Schizophr Res. 2016;174(1-3):156-60. Search in Google Scholar

42 Gomez L, Stubbs B, Shirazi A, Vancampfort D, Gaughran F, Lally J. Lower bone mineral density at the hip and lumbar spine in people with psychosis versus controls: a comprehensive review and seletal site-specific meta-analysis. Curr Osteoporos Rep. 2016;14(6):249-259. Search in Google Scholar

43 Zhang B, Deng L, Wu H, Lu X, Peng L, Wu R, et al. Relationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and β-CrossLaps. Schizophr Res. 2016;176(2-3):259-63. Search in Google Scholar

44 Bozec A, Zaiss MM. T regulatory cells in bone remodelling. Curr Osteoporos Rep. 2017;15(3):121-5. Search in Google Scholar

45 Liu H, Luo T, Tan J, Li M, Guo J. Osteoimmunology’ Offers New Perspectives for the Treatment of Pathological Bone Loss. Curr Pharm Des. 2017;23(41):6272-8. Search in Google Scholar

46 Azizieh F, Raghupathy R, Shehab D, Al-Jarallah K, Gupta R. Cytokine profiles in osteoporosis suggest a proresorptive bias. Menopause. 2017;24(9):1057-64. Search in Google Scholar

47 De Pablo P, Cooper MS, Buckley CD. Association between bone mineral density and C-reactive protein in a large population-based sample. Arthritis Rheum. 2012;64(8):2624-31. Search in Google Scholar

48 Borovcanin MM, Jovanovic I, Radosavljevic G, Pantic J, Minic Janicijevic S, Arsenijevic N, Lukic ML. Interleukin-6 in Schizophrenia-Is there a therapeutic relevance? Front Psychiatry. 2017;8:221. Search in Google Scholar

49 Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras de Psiquiatr. 2011;33(3):268-74. Search in Google Scholar

50 Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, et al. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr Res. 2013;147(1):103-9. Search in Google Scholar

51 Cui J, Liu H, Shao J, Xu DM, Wang Y, Fei Z, et al. Prevalence, risk factors and clinical characteristics of osteoporosis in Chinese inpatients with schizophrenia. Schizophr Res. 2018;195:488-94. Search in Google Scholar

52 Vancampfort D, Knapen J, Probst M, Scheewe T, Remans S, De Hert M. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 2012;125(5):352-62. Search in Google Scholar

53 Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–41. Search in Google Scholar

54 Freyberg Z, Aslanoglou D, Shah R, Ballon JS. Intrinsic and antipsychotic drug-induced metabolic dysfunction in schizophrenia. Front Neurosci. 2017;11:432. Search in Google Scholar

55 Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010;10(3):209-16. Search in Google Scholar

56 Curcic D, Stojmenovic T, Djukic-Dejanovic S, Dikic N, Vesic-Vukasinovic M, Radivojevic N, et al. Positive impact of prescribed physical activity on symptoms of schizophrenia: randomized clinical trial. Psychiatr Danub. 2017;29(4):459-65. Search in Google Scholar

57 Stubbs B, Gaughran F, Mitchell AJ, De Hert M, Farmer R, Soundy A, et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):126-33. Search in Google Scholar

58 Pillinger T, D’Ambrosio E, McCutcheon R, D Howes O. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol Psychiatry. 2019;24(6):776-94. Search in Google Scholar

59 Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385-403. Search in Google Scholar

60 Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab. 2014;25(11):593-600. Search in Google Scholar